CA1341100C - Sequences determinees d'adn derivees du genome du virus de papillome, leurs utilisations a des fins diagnostique in vitro et la production de compositions antigeniques - Google Patents
Sequences determinees d'adn derivees du genome du virus de papillome, leurs utilisations a des fins diagnostique in vitro et la production de compositions antigeniquesInfo
- Publication number
- CA1341100C CA1341100C CA000532925A CA532925A CA1341100C CA 1341100 C CA1341100 C CA 1341100C CA 000532925 A CA000532925 A CA 000532925A CA 532925 A CA532925 A CA 532925A CA 1341100 C CA1341100 C CA 1341100C
- Authority
- CA
- Canada
- Prior art keywords
- hpv
- dna
- nucleic acid
- papillomavirus
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241001631646 Papillomaviridae Species 0.000 title claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 title description 20
- 238000004519 manufacturing process Methods 0.000 title description 6
- 239000000203 mixture Substances 0.000 title description 5
- 230000000890 antigenic effect Effects 0.000 title description 2
- 238000000338 in vitro Methods 0.000 title description 2
- 239000000523 sample Substances 0.000 claims abstract description 21
- 239000002773 nucleotide Substances 0.000 claims abstract description 16
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 16
- 238000001514 detection method Methods 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 14
- 241000701806 Human papillomavirus Species 0.000 claims description 12
- 238000009396 hybridization Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000001574 biopsy Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 231100000590 oncogenic Toxicity 0.000 claims description 5
- 230000002246 oncogenic effect Effects 0.000 claims description 5
- 231100000588 tumorigenic Toxicity 0.000 claims description 4
- 230000000381 tumorigenic effect Effects 0.000 claims description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 8
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 239000003623 enhancer Substances 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 108091092724 Noncoding DNA Proteins 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 210000004392 genitalia Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000701822 Bovine papillomavirus Species 0.000 description 5
- 108091027569 Z-DNA Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 208000019065 cervical carcinoma Diseases 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000709701 Human poliovirus 1 Species 0.000 description 2
- 241000829111 Human polyomavirus 1 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091036333 Rapid DNA Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 101150082674 E2 gene Proteins 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 241000201835 Froelichia floridana Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000617043A CA1341329C (fr) | 1987-03-25 | 1987-03-25 | Sequences d'adn determinees provenant du genome du papillomavirus, ainsi que leur usage a des fins diagnostiques in vitro ou pour la synthese de compositions antigeniques |
CA000532925A CA1341100C (fr) | 1987-03-25 | 1987-03-25 | Sequences determinees d'adn derivees du genome du virus de papillome, leurs utilisations a des fins diagnostique in vitro et la production de compositions antigeniques |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000532925A CA1341100C (fr) | 1987-03-25 | 1987-03-25 | Sequences determinees d'adn derivees du genome du virus de papillome, leurs utilisations a des fins diagnostique in vitro et la production de compositions antigeniques |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000617043A Division CA1341329C (fr) | 1987-03-25 | 1987-03-25 | Sequences d'adn determinees provenant du genome du papillomavirus, ainsi que leur usage a des fins diagnostiques in vitro ou pour la synthese de compositions antigeniques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1341100C true CA1341100C (fr) | 2000-09-26 |
Family
ID=4135279
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000617043A Expired - Lifetime CA1341329C (fr) | 1987-03-25 | 1987-03-25 | Sequences d'adn determinees provenant du genome du papillomavirus, ainsi que leur usage a des fins diagnostiques in vitro ou pour la synthese de compositions antigeniques |
CA000532925A Expired - Lifetime CA1341100C (fr) | 1987-03-25 | 1987-03-25 | Sequences determinees d'adn derivees du genome du virus de papillome, leurs utilisations a des fins diagnostique in vitro et la production de compositions antigeniques |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000617043A Expired - Lifetime CA1341329C (fr) | 1987-03-25 | 1987-03-25 | Sequences d'adn determinees provenant du genome du papillomavirus, ainsi que leur usage a des fins diagnostiques in vitro ou pour la synthese de compositions antigeniques |
Country Status (1)
Country | Link |
---|---|
CA (2) | CA1341329C (fr) |
-
1987
- 1987-03-25 CA CA000617043A patent/CA1341329C/fr not_active Expired - Lifetime
- 1987-03-25 CA CA000532925A patent/CA1341100C/fr not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA1341329C (fr) | 2001-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5876723A (en) | Purified human papillomavirus type 33 (HPV-33) peptides as an immunogenic composition | |
Cole et al. | Genome organization and nucleotide sequence of human papillomavirus type 33, which is associated with cervical cancer | |
JP2742257B2 (ja) | 乳頭腫ウイルスに対するプローブ及び乳頭腫ウイルス感染の検出法 | |
US5057411A (en) | Type-specific papillomavirus DNA sequences and peptides | |
US5342930A (en) | Isolated DNA of human papillomavirus type 54(HPV54) | |
US5665535A (en) | Polypeptides encoded by DNA sequences derived from the genome of the papillomavirus HPV39, antibodies thereto, and their use in in vitro diagnosis | |
US5753233A (en) | Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18 | |
JP2716120B2 (ja) | 乳頭腫ウイルスプローブ及び乳頭腫ウイルス感染のインビトロ診断方法 | |
CA1341100C (fr) | Sequences determinees d'adn derivees du genome du virus de papillome, leurs utilisations a des fins diagnostique in vitro et la production de compositions antigeniques | |
EP1140974B1 (fr) | Dosage neutralisant utilisant des particules veriformes du papillomavirus humain | |
JPH05192200A (ja) | ヒトパピローマウイルスの検出方法 | |
Jochmus et al. | Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by Western blot analysis: type-specific reaction of anti-HPV 16 antibodies | |
Moro et al. | Bacterial expression and immunological detection of human papillomavirus type 16 E7 protein | |
JPH05502792A (ja) | 生殖器腫瘍を伴い得るパピローマウイルス感染のインビトロ診断に主として使用されるパピローマウイルス(hpv63)プローブ、並びにこのパピローマウイルスに遺伝的且つ免疫学的に関連した産物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |
Effective date: 20170926 |